Search Results - "Alyasova, A."

Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study by Hesketh, P.J., Rossi, G., Rizzi, G., Palmas, M., Alyasova, A., Bondarenko, I., Lisyanskaya, A., Gralla, R.J.

“…NEPA is a novel oral fixed-dose combination of netupitant (NETU), a new highly selective neurokinin-1 (NK1) receptor antagonist (RA) and palonosetron (PALO), a…”
Get full text

Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4) by Motzer, R.J., Alyasova, A., Ye, D., Karpenko, A., Li, H., Alekseev, B., Xie, L., Kurteva, G., Kowalyszyn, R., Karyakin, O., Neron, Y., Cosgriff, T., Collins, L., Brechenmacher, T., Lin, C., Morgan, L., Yang, L.

“…RECORD-1 demonstrated clinical benefit of everolimus in patients with metastatic renal cell carcinoma (mRCC) previously treated with sunitinib, sorafenib, or…”
Get full text

Messenger RNA of FCGR3A and FCGR3B Genes as Monitoring Markers of Clear Cell Renal Adenocarcinoma (a Pilot Study) by Alyasova, A V, Amoev, Z V, Shkola, O O, Novikov, D V, Selivanova, S G, Novikov, V V

“…was to assess the capabilities of mRNA genes encoding CD16a ( ) and CD16b ( ) in tumor samples from patients with renal cancer, and characterize the tumor…”
Get full text

OC-021: Biomarker results from BERIL-1: buparlisib and paclitaxel in patients with platinum-pretreated SCCHN by Soulières, D, Faivre, S, Mesía, R, Remenár, E, Li, S.H, Karpenko, A, Dechaphunkul, A, Keilholz, U, Kiss, L, Lin, J.C, Nagarkar, R, Tamás, L, Kim, S.B, Erfán, J, Alyasova, A, Yovine, A, Le Mouhaër, S, Solovieff, N, Turri, S, Licitra, L

Get full text

2620 RECORD-4 multicenter phase 2 trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC): Pooled anti-VEGF cohort subanalysis by Alekseev, B, Yang, L, Alyasova, A, Ye, D, Karpenko, A, Li, H, Xie, L, Kurteva, G, Kowalyszyn, R, Karyakin, O, Neron, Y, Cosgriff, T, Collins, L, Brechenmacher, T, Lin, J, Morgan, L, Motzer, R

Get full text

2634 RECORD-4 multicenter phase 2 trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC): Asian versus non-Asian population subanalysis by Yang, L, Alyasova, A, Ye, D, Karpenko, A, Li, H, Alekseev, B, Xie, L, Kurteva, G, Kowalyszyn, R, Karyakin, O, Neron, Y, Cosgriff, T, Collins, L, Brechenmacher, T, Lin, J, Morgan, L, Motzer, R

Get full text

Tumor M2-Pyruvate Kinase, Matrix Carbonic Anhydrase IX, and Metalloproteinase 9 - Novel Prognostic Markers of Renal Cell Carcinoma by Amoev, Z V, Alyasova, A V, Gorshkova, T N, Samsonova, E I, Strokina, E V, Kontorshchikova, K N

“…was to assess the possibility of using plasma levels of tumor M2-pyruvate kinase (Tu M2-PK), matrix carbonic anhydrase IX (CA9), and matrix metalloproteinase 9…”
Get full text

The level of Hydrogen Peroxide in HeLa Cells in an Ozonated Medium by Kontorshchikova, K. N., Belova, A. S., Dudenkova, V. V., Orlova, A. G., Terent’ev, I. G., Tsybusov, S. N., Alyasova, A. V.

“…We studied the role of hydrogen peroxide in the response of tumor cells to treatment with ozonated culture medium. Changes of the level of hydrogen peroxide in…”
Get full text

Associations of lipoproteins with bone mass in postmenopausal women by Skripnikova, I A, Abirova, E S, Alyasova, P A, Alikhanova, N A, Khudyakov, M B, Vygodin, V A

“…To study an association between blood lipid composition and bone mass in Russian postmenopausal women. The cross-sectional study included 373 postmenopausal…”
Get full text

The CD16A and CD16B mRNA level as potential immunological marker in colorectal cancer by Krasnogorova, N. V., Novikov, D. V., Fomina, S. G., Alyasova, A. V., Magomedov, M. A., Novikov, V. V., Karaulov, A. V.

“…The purpose of this study is to evaluate mRNA levels of genes encoding CD16A ( FCGR3A ) and CD16B ( FCGR3B ) in peripheral blood and tumors of colorectal…”
Get full text

Heterogeneous CD38 expression in tumor tissues of patients with colorectal cancer by Perenkov, A. D., Novikov, D. V., Sakharnov, N. A., Alyasova, A. V., Utkin, O. V., Baryshnikov, A. Yu, Novikov, V. V.

“…The CD38 gene encodes a membrane-bound protein that takes part in cell adhesion and catalyzes the formation of cyclic ADP-ribose. The presence of the full-size…”
Get full text

239O RECORD-4: Multicenter phase 2 trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC): Asian versus non-Asian population subanalysis by Yang, L., Alyasova, A., Ye, D., Karpenko, A., Li, H., Alekseev, B., Xie, L., Kurteva, G., Kowalyszyn, R.D., Karyakin, O., Nerón, Y.V., Cosgriff, T.M., Collins, L., Brechenmacher, T., Lin, J.C., Morgan, L., Motzer, R.

Get full text

Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study by Hesketh, P J, Rossi, G, Rizzi, G, Palmas, M, Alyasova, A, Bondarenko, I, Lisyanskaya, A, Gralla, R J

“…NEPA is a novel oral fixed-dose combination of netupitant (NETU), a new highly selective neurokinin-1 (NK ) receptor antagonist (RA) and palonosetron (PALO), a…”
Get full text